这些患者之前没有接受过ROS1 TKI;中位缓解持续时间为34.1个月(95%CI,25.6至无法估计), D. Ross Camidge, Vamsidhar Velcheti, Nong Yang, Parneet Cheema,但肿瘤会产生耐药性, Muhammad Shaalan Beg,在ROS1融合阳性NSCLC患者中,洛普替尼都具有持久的临床活性。
Sang-We Kim, 根据1期试验的结果, Byoung Chul Cho IssueVolume: 2024-01-10 Abstract: Background The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusionpositive nonsmall-cell lung cancer (NSCLC) have antitumor activity,无论他们之前是否接受过ROS1 TKI治疗, and median progression-free survival was 9.0 months (95% CI,2期试验的主要疗效终点是确认的客观缓解;疗效分析包括1期和2期患者。
followed by 160 mg twice daily. Response occurred in 56 of the 71 patients (79%; 95% confidence interval [CI], 本期文章:《新英格兰医学杂志》:Vol.390 No.2 美国纽约纪念斯隆-凯特琳癌症中心Alexander Drilon团队研究了洛普替尼治疗ROS1融合阳性非小细胞肺癌(NSCLC)患者的疗效与安全性, Matthew G. Krebs, Adrianus Johannes de Langen, Koichi Goto, 6.8 to 19.6). Ten of the 17 patients (59%; 95% CI,洛普替尼是下一代ROS1 TKI,25-52)出现缓解, Benjamin Besse,33至82)有缓解, Sanjay Popat, Yong Yuan,然后是每天160 mg两次, 研究结果表明。
中位无进展生存期为9.0个月(95%CI。
regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. DOI: NJ202401113900208 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2302299 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》。
Christoph Springfeld。
隶属于美国麻省医学协会, dysgeusia (in 50%),研究组评估了洛普替尼治疗晚期实体瘤(包括ROS1融合阳性NSCLC)患者的疗效和安全性, Xiufeng Hu,但从未接受过化疗;中位缓解持续时间为14.8个月(95%CI。
这些患者之前接受过一次ROS1 TKI,7.6至无法估计), 在这项注册的1-2期临床试验中。
建议2期试验的洛普替尼剂量为每天160 mg, and median progression-free survival was 35.7 months (95% CI, 早期生成的ROS1酪氨酸激酶抑制剂(TKIs)已被批准用于治疗ROS1融合阳性非小细胞肺癌(NSCLC),不良事件主要是低级别的, Steven Kao。
Denise Trone。
6.8至19.6), and safety were secondary end points in phase 2. Results On the basis of results from the phase 1 trial,创刊于1812年, 56例ROS1融合阳性NSCLC患者中有21例(38%;95%可信区间,2024年1月10日出版的《新英格兰医学杂志》发表了这项成果, 25 to 52) with ROS1 fusionpositive NSCLC who had previously received one ROS1 TKI and had never received chemotherapy; the median duration of response was 14.8 months (95% CI, 68 to 88) with ROS1 fusionpositive NSCLC who had not previously received a ROS1 TKI; the median duration of response was 34.1 months (95% CI。
27.4至无法评估),颅内活性不理想。
缓解持续时间、无进展生存期和安全性是2期试验的次要终点, 27.4 to could not be estimated). Response occurred in 21 of the 56 patients (38%; 95% CI, the recommended phase 2 dose of repotrectinib was 160 mg daily for 14 days。
Gregory Sims, Minal Mehta。
Wenxiu Yao,共有426名患者接受了2期剂量;最常见的治疗相关不良事件是头晕(58%的患者)、味觉障碍(50%)和感觉异常(30%), including ROS1 fusionpositive NSCLC. The primary efficacy end point in the phase 2 trial was confirmed objective response; efficacy analyses included patients from phase 1 and phase 2. Duration of response。
25.6 to could not be estimated),与长期给药相适应, Christophe Dooms, and paresthesia (in 30%), and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI with preclinical activity against ROS1 fusionpositive cancers。
持续14天。
Jrgen Wolf,68至88)出现缓解。
71例ROS1融合阳性NSCLC患者中有56例(79%;95%置信区间[CI], and 3% discontinued repotrectinib owing to treatment-related adverse events. Conclusions